Natalia Rodriguez-Muela
Selective Neuronal Vulnerability in Neurodegenerative Diseases
Dr. Natalia Rodriguez-Muela
Group Leader
Tatzberg 41
01307  Dresden

Areas of investigation/research focus

Why a given neuropathology does not impact all neurons of the same type to a similar level? This is a fascinating question in neurodegeneration research that remains unanswered and represents the main focus of Rodriguez-Muela lab.

In most neurodegenerative diseases certain neuronal subgroups degenerate fast while others, carrying the same mutations -if any-, subjected to theoretically analogous stress and displaying comparable functional properties remain unaffected, even at the latest stages of the disease. Motor neuron diseases are a group of disorders in which motor neurons (MNs) of the spinal cord and/or the motor cortex are the primary cell type affected where this perplexing feature can also be observed. Using a variety of approaches ranging from cellular biology techniques and live imaging to genome editing and single cell genomics, and utilizing hiPSC together with transgenic animal models, we investigate the molecular mechanisms underlying such selective MN death. We devote a special focus at exploring the molecular basis of proteostasis failure -major causative event in neurodegeneration-, and at examining the contribution of cell autonomous and non-cell autonomous factors to the selective MN loss. Our ultimate goal is to understand the molecular origin of this distinctive neuronal vulnerability to design effective therapeutics targeting specific neuronal subtypes or phases of the disease.

 more Infos

The key aspect of selective motor neuron death in motor neuron diseases had been difficult to address using available mouse models. We use as main model system a human induced pluripotent stem cell (iPSC)-based approach and discovered that even within a single genetic background, MNs display a wide diversity of SMN levels –protein essential for MN survival–, and that those cells with low SMN are more susceptible to die. This correlation holds true in MNs expressing mutations causing the most common motor neuron diseases (amyotrophic lateral sclerosis or ALS and spinal muscular atrophy or SMA) and even in MNs obtained from unaffected patients. This discovery led to a new understanding of the importance of cell diversity in the progression of these diseases and helped to explain why there is a “survivor” population of MNs. However, there is so much that we still ignore. Some of the question that we want to answer are: what are the main similarities and differences between the surviving ALS and SMA MNs?, are there factors/pathways shared between neuronal types unaffected in MNDs that explain their protection?, what is the molecular basis of SMN heterogeneity across MN populations? Ultimately, why do many neurons degenerate while some remain fully resistant?


Rodriguez-Muela N, Parkhitko A, Grass T, Gibbs R, Norabuena E, Perrimon N, Singh R, Rubin LL. Blocking p62/SQSTM1- dependent SMN degradation ameliorates the Spinal Muscular Atrophy disease phenotype. J Clin Invest. 2018 Jul 02; 127:3008-3023. doi: 10.1172/JCI95231
Rodriguez-Muela N1*, Litterman NK1, Norabuena EM, Mull JL, Galazo MJ, Sun C, Ng SY, Makhortova NR, White A, Lynes MM, Chung WK, Davidow LS, Macklis JD, Rubin LL. Single-Cell Analysis of SMN Reveals Its Broader Role in Neuromuscular Disease. Cell Reports. 2017 Feb 07; 18:1484-1498. doi: 10.1016/j.celrep.2017.01.035
Ng SY1, Soh BS1, Rodriguez-Muela N, Hendrickson DG, Price F, Rinn JL, Rubin LL. Genome-wide RNA-Seq of Human Motor Neurons Implicates Selective ER Stress Activation in Spinal Muscular Atrophy. Cell Stem Cell. 2015 Nov 05; 17:569-84. doi: 10.1016/j.stem.2015.08.003
Rodríguez-Muela N, Koga H, et al. Balance between autophagic pathways preserves retinal homeostasis. Aging Cell. 2019 Aug 02; 12:478-88. doi: 10.1111/acel.12072
Rodríguez-Muela N, Germain F, et al. Autophagy promotes survival of retinal ganglion cells after optic nerve axotomy in mice. Cell Death Differ. 2019 Aug 02; 19:162-9. doi: 10.1038/cdd.2011.88


Thursdays 1:30-4:30 pm

Patients +49 800-7799001

(free of charge)

Professionals +49 180-779900

(9 Cent/Min. German landline, mobile and out of Germany possibly more expensive)

Welcome to our website, here you can inform yourself basically cookie-free.

We would be pleased if you would allow a cookie to be set for analysis purposes in order to optimise our provided information. All data are pseudonymous and are only used by the DZNE. We deliberately avoid third-party cookies. You can deselect this setting at any time here.

Your browser allows the setting of cookies: